Study identifier:D8220R00055
ClinicalTrials.gov identifier:NCT06170671
EudraCT identifier:N/A
CTIS identifier:N/A
Observational, secondary data collection study to describe acalabrutinib treatment outcomes in chronic lymphocytic leukemia patients in real-life setting in Romania
Chronic Lymphocytic Leukemia
N/A
No
Non interventional study
All
250
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Cohort 1 December 2023 - collecting data retrospectively from patients routinely initiated on acalabrutinib between January - December 2023 | Drug: Non interventional study CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection Other Name: Not applicable |
Cohort 2 December 2024-collecting data retrospectively from patients routinely initated on acalabrutinib between January - December 2024 | Drug: Non interventional study CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection Other Name: Not applicable |